AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19526754 — intervention group
Group type: COMPARATOR
Intervention: Western medical conventional treatment (Control group).
Number of subjects: 63
Study 17338713 — intervention group
Group type: EXPERIMENTAL
Intervention: VDD pacing
Number of subjects: 129
Study 15476445 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (Genotropin) for six months followed by 12 months of GH for all participants
Number of subjects: 17
Study 15476445 — intervention group
Group type: COMPARATOR
Intervention: Placebo for six months
Number of subjects: 17
Study 10831020 — intervention group
Group type: COMPARATOR
Intervention: Zaleplon 10 mg
Number of subjects: 24
Study 10831020 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 24
Study 10831020 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 20 mg
Number of subjects: 24
Study 10831020 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon 20 mg
Number of subjects: 24
Study 10831020 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 24
Study 10831020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9629724 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Vacuum Aspiration (MVA)
Number of subjects: 30
Study 9629724 — intervention group
Group type: COMPARATOR
Intervention: Sharp Curettage (SC)
Number of subjects: 30
Study 1474771 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal neostigmine (2 mg)
Number of subjects: 7
Study 1474771 — intervention group
Group type: COMPARATOR
Intervention: Control (without intraperitoneal neostigmine)
Number of subjects: 7
Study 6084925 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigen-free diet (Vivasorb)
Number of subjects: 33
Study 6084925 — intervention group
Group type: COMPARATOR
Intervention: Placebo diet
Number of subjects: 33
Study 30744590 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness Management and Recovery (IMR) program
Number of subjects: 198
Study 30744590 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 198
Study 29538411 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-collected vaginal HPV DNA swab
Number of subjects: 150
Study 29538411 — intervention group
Group type: COMPARATOR
Intervention: Provider-collected cervical HPV swab (gold standard)
Number of subjects: 150
Study 26618797 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to e‐cigarette vaping video (n = 38)
Number of subjects: 78
Study 26618797 — intervention group
Group type: COMPARATOR
Intervention: Bottled water drinking video (n = 40)
Number of subjects: 78
Study 1447654 — intervention group
Group type: EXPERIMENTAL
Intervention: Thickened feedings with rice cereal
Number of subjects: 25
Study 1447654 — intervention group
Group type: COMPARATOR
Intervention: Unthickened feedings
Number of subjects: 25
Study 22877811 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal Medical Therapy (OMT)
Number of subjects: 1381
Study 22877811 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention + Optimal Medical Therapy (PCI + OMT)
Number of subjects: 1381
Study 22877811 — intervention group
Group type: COMPARATOR
Intervention: Both OMT and PCI + OMT
Number of subjects: 1381
Study 20528213 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg suppositories
Number of subjects: 232
Study 20528213 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg tablets
Number of subjects: 232
Study 20528213 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 232
Study 19118733 — intervention group
Group type: EXPERIMENTAL
Intervention: Early elective surgery
Number of subjects: 1090
Study 19118733 — intervention group
Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 1090
Study 16422810 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil (5-20 mg)
Number of subjects: 354
Study 16422810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study 12697484 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal cushion resection
Number of subjects: 48
Study 12697484 — intervention group
Group type: COMPARATOR
Intervention: Milligan‐Morgan hemorrhoidectomy
Number of subjects: 48
Study 10381294 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous platelet aggregation
Number of subjects: 2873
Study 10381294 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 2873
Study 10381294 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower HDL-levels
Number of subjects: 2873
Study 10381294 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated diastolic blood pressure
Number of subjects: 2873
Study 10381294 — intervention group
Group type: EXPERIMENTAL
Intervention: Slightly elevated blood glucose
Number of subjects: 2873
Study 10381294 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fibrinogen levels
Number of subjects: 2873
Study 10381294 — intervention group
Group type: EXPERIMENTAL
Intervention: None of the other hemostatic parameters
Number of subjects: 2873
Study 8885615 — intervention group
Group type: EXPERIMENTAL
Intervention: Canvas shoes
Number of subjects: 0
Study 8885615 — intervention group
Group type: COMPARATOR
Intervention: Plastazote/moulded shoes
Number of subjects: 0
Study 2064880 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamorphine
Number of subjects: 12
Study 2064880 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 12
Study 500834 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium ingestion (0.0, 0.5, 1.5, and 3.0 g of elemental calcium as gluconate)
Number of subjects: 10
Study 500834 — intervention group
Group type: COMPARATOR
Intervention: Control (ingestion of distilled water)
Number of subjects: 10
Study 31538444 — intervention group
Group type: EXPERIMENTAL
Intervention: Decontaminant material (sulfonic/sulphuric acid solution, HybenX, EPIEN Medical)
Number of subjects: 60
Study 31538444 — intervention group
Group type: COMPARATOR
Intervention: Sodium hypochlorite 5% (control group)
Number of subjects: 60
Study 28005225 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 81-8973 (50 IU/kg)
Number of subjects: 18
Study 28005225 — intervention group
Group type: COMPARATOR
Intervention: rAHF-PFM (50 IU/kg)
Number of subjects: 18
Study 25462664 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit forever goal
Number of subjects: 808
Study 25462664 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence goal
Number of subjects: 808
Study 25462664 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower educational level
Number of subjects: 808
Study 23595929 — intervention group
Group type: EXPERIMENTAL
Intervention: Templated 4+1 model of residency
Number of subjects: 0
Study 21619622 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-serve version of SHARE
Number of subjects: 120
Study 21619622 — intervention group
Group type: COMPARATOR
Intervention: Self-serve version of SHARE
Number of subjects: 120
Study 19266588 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Magnitude Estimation (DME) scaling method
Number of subjects: 27
Study 19266588 — intervention group
Group type: COMPARATOR
Intervention: Equal Appearing Interval (EAI) scaling method
Number of subjects: 27
Study 17062601 — intervention group
Group type: EXPERIMENTAL
Intervention: TPB questionnaire plus leaflet-like intervention
Number of subjects: 573
Study 17062601 — intervention group
Group type: COMPARATOR
Intervention: TPB questionnaire only
Number of subjects: 573
Study 16896425 — intervention group
Group type: EXPERIMENTAL
Intervention: OxyMask
Number of subjects: 26
Study 16896425 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified OxyMask
Number of subjects: 26
Study 16896425 — intervention group
Group type: COMPARATOR
Intervention: Venturi mask
Number of subjects: 26
Study 14657773 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask
Number of subjects: 46
Study 14657773 — intervention group
Group type: COMPARATOR
Intervention: Face mask
Number of subjects: 46
Study 9929017 — intervention group
Group type: EXPERIMENTAL
Intervention: leflunomide (100 mg daily on days 1-3, then 20 mg daily)
Number of subjects: 358
Study 9929017 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 358
Study 9929017 — intervention group
Group type: EXPERIMENTAL
Intervention: sulphasalazine (0.5 g daily, titrated to 2.0 g daily at week 4)
Number of subjects: 358
Study 9929017 — intervention group
Group type: EXPERIMENTAL
Intervention: leflunomide
Number of subjects: 358
Study 9929017 — intervention group
Group type: EXPERIMENTAL
Intervention: sulphasalazine
Number of subjects: 358
Study 9929017 — intervention group
Group type: EXPERIMENTAL
Intervention: leflunomide and sulphasalazine
Number of subjects: 358
Study 7486098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 1 mg/mL (0.1%)
Number of subjects: 37
Study 7486098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 2 mg/mL (0.2%)
Number of subjects: 37
Study 7486098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 3 mg/mL (0.3%)
Number of subjects: 37
Study 7486098 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 2.5 mg/mL (0.25%)
Number of subjects: 37
Study 7486098 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride 0.9%)
Number of subjects: 37
Study 7486098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (various doses)
Number of subjects: 37
Study 7486098 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (2.5 mg/mL)
Number of subjects: 37
Study 7486098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine and Bupivacaine
Number of subjects: 37
Study 2354484 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg once daily
Number of subjects: 24
Study 2354484 — intervention group
Group type: COMPARATOR
Intervention: Nicardipine 20 mg thrice daily
Number of subjects: 24
Study 466753 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 20 micrograms NAB 365 (clenbuterol)
Number of subjects: 9
Study 466753 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 250 micrograms terbutaline
Number of subjects: 9
Study 466753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31855717 — intervention group
Group type: EXPERIMENTAL
Intervention: SDF Intervention positioning
Number of subjects: 34
Study 31855717 — intervention group
Group type: COMPARATOR
Intervention: Vertical Control
Number of subjects: 34
Study 29801515 — intervention group
Group type: EXPERIMENTAL
Intervention: DC vaccination as an add-on to the standard therapy
Number of subjects: 136
Study 29801515 — intervention group
Group type: COMPARATOR
Intervention: Standard radio/temozolomide chemotherapy
Number of subjects: 136
Study 27503851 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium diet
Number of subjects: 71
Study 27503851 — intervention group
Group type: COMPARATOR
Intervention: Low-sodium diet
Number of subjects: 71
Study 23944875 — intervention group
Group type: EXPERIMENTAL
Intervention: MD-Logic artificial pancreas (closed-loop)
Number of subjects: 15
Study 23944875 — intervention group
Group type: COMPARATOR
Intervention: Sensor-augmented pump therapy (control)
Number of subjects: 15
Study 23009149 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and nutrition (EN)
Number of subjects: 117
Study 23009149 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem solving therapy (PST)
Number of subjects: 117
Study 23009149 — intervention group
Group type: COMPARATOR
Intervention: Non-EN
Number of subjects: 117
Study 23009149 — intervention group
Group type: COMPARATOR
Intervention: Non-PST
Number of subjects: 117
Study 21077572 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (CIT) 20 mg
Number of subjects: 60
Study 21077572 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (IMI) 75 mg
Number of subjects: 60
Study 21077572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 18518892 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (50 mg once daily for moderate renal insufficiency; 25 mg once daily for severe renal insufficiency)
Number of subjects: 91
Study 18518892 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by glipizide (2.5 or 5 mg/day, uptitrated to max 20 mg/day)
Number of subjects: 91
Study 18518892 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 91
Study 18518892 — intervention group
Group type: COMPARATOR
Intervention: Placebo/glipizide
Number of subjects: 91
Study 16203961 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 36
Study 16203961 — intervention group
Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 36
Study 11828246 — intervention group
Group type: EXPERIMENTAL
Intervention: C (caffeine 4 mg/kg)
Number of subjects: 12
Study 11828246 — intervention group
Group type: EXPERIMENTAL
Intervention: E (ephedrine 0.8 mg/kg)
Number of subjects: 12
Study 11828246 — intervention group
Group type: EXPERIMENTAL
Intervention: C + E (caffeine 4 mg/kg + ephedrine 0.8 mg/kg)
Number of subjects: 12
Study 11828246 — intervention group
Group type: COMPARATOR
Intervention: P (placebo)
Number of subjects: 12
Study 11828246 — intervention group
Group type: EXPERIMENTAL
Intervention: E (ephedrine 0.8 mg/kg) and C + E
Number of subjects: 12
Study 11828246 — intervention group
Group type: EXPERIMENTAL
Intervention: C + E
Number of subjects: 12
Study 10072747 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention (2-year program including classes, mailed self-help materials, and personalized dietary feedback)
Number of subjects: 5042
Study 10072747 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 5042
Study 8547834 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation of retinol (25,000 IU) for 5 years in SKICAP-AK trial
Number of subjects: 3519
Study 8547834 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation of retinol (25,000 IU) or 13‐cis‐retinoic acid (5 or 10 mg) for 3 years in SKICAP-S/B trial
Number of subjects: 3519
Study 2310247 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine cardioplegia (0.25 mg/L)
Number of subjects: 33
Study 2310247 — intervention group
Group type: COMPARATOR
Intervention: Standard potassium cardioplegia
Number of subjects: 33
Study 7003700 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus chemotherapy (RT+CT)
Number of subjects: 237
Study 7003700 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (TNI)
Number of subjects: 237
Study 30602360 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning (4, 30 seconds PTCA inflations/deflations) + PCI (n=65)
Number of subjects: 122
Study 30602360 — intervention group
Group type: COMPARATOR
Intervention: Routine PCI (n=57)
Number of subjects: 122
Study 30602360 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning
Number of subjects: 122
Study 30602360 — intervention group
Group type: COMPARATOR
Intervention: Routine PCI
Number of subjects: 122
Study 28109295 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg qd
Number of subjects: 42
Study 28109295 — intervention group
Group type: COMPARATOR
Intervention: glimepiride 1-4 mg qd
Number of subjects: 42
Study 28109295 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study 25844905 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberative decision strategies
Number of subjects: 0
Study 25844905 — intervention group
Group type: COMPARATOR
Intervention: Intuitive decision strategies
Number of subjects: 0
Study 24064010 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 13608
Study 24064010 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 13608
Study 24064010 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both treatments)
Number of subjects: 13608
Study 24064010 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (sensitivity analysis excluding periprocedural acute-ST)
Number of subjects: 13608
Study 20428935 — intervention group
Group type: EXPERIMENTAL
Intervention: $10 CVS gift card incentive
Number of subjects: 550
Study 20428935 — intervention group
Group type: COMPARATOR
Intervention: 30‐min prepaid phone card
Number of subjects: 550
Study 19592292 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Dk (etafilcon A) soft contact lenses
Number of subjects: 20
Study 19592292 — intervention group
Group type: COMPARATOR
Intervention: High Dk (lotrafilcon A) soft contact lenses
Number of subjects: 20
Study 17449179 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 12
Study 17449179 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study 15118806 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam and alcohol
Number of subjects: 24
Study 15118806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11110572 — intervention group
Group type: EXPERIMENTAL
Intervention: HoLRP
Number of subjects: 120
Study 11110572 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 120
Study 9332804 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional tooth cleaning and oral health education program (test)
Number of subjects: 404
Study 9332804 — intervention group
Group type: COMPARATOR
Intervention: Standard preventive program (control)
Number of subjects: 404
Study 8476960 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin 300 mg once a day
Number of subjects: 211
Study 8476960 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 200 mg day 1 and 100 mg day 2-10
Number of subjects: 211
Study 8476960 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 211
Study 8476960 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin
Number of subjects: 211
Study 4023557 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel treatment
Number of subjects: 34
Study 30683523 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous TXA (15mg/kg)
Number of subjects: 78
Study 30683523 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular TXA (2g)
Number of subjects: 78
Study 30683523 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 78
Study 29716576 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-week online mindfulness training
Number of subjects: 160
Study 29716576 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted control group
Number of subjects: 160
Study 24800718 — intervention group
Group type: EXPERIMENTAL
Intervention: Noxious thermal stimulation (46°C‐47°C heat and 7°C‐8°C cold)
Number of subjects: 16
Study 24800718 — intervention group
Group type: COMPARATOR
Intervention: Innocuous thermal stimulation (40°C‐41°C heat and 20°C‐21°C cold)
Number of subjects: 16
Study 23272199 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadership training program (6-month duration)
Number of subjects: 180
Study 23272199 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 180
Study 23272199 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadership training program (6-month duration) among female students
Number of subjects: 180
Study 23272199 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training) among female students
Number of subjects: 180
Study 20331372 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Number of subjects: 16
Study 20331372 — intervention group
Group type: COMPARATOR
Intervention: Control (heat, massage, exercises, home program)
Number of subjects: 16
Study 18317788 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rifampicin
Number of subjects: 0
Study 18317788 — intervention group
Group type: COMPARATOR
Intervention: Submucosal placentrex injection
Number of subjects: 0
Study 15741048 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea (GT) - 2 cups containing approximately 250 mg of total catechins
Number of subjects: 0
Study 15741048 — intervention group
Group type: COMPARATOR
Intervention: Control group - same controlled diet without GT
Number of subjects: 0
Study 12512987 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% carbamide peroxide bleaching gel + potassium nitrate in a custom tray (Colgate Platinum Gentle Plus)
Number of subjects: 34
Study 12512987 — intervention group
Group type: COMPARATOR
Intervention: 6.0% hydrogen peroxide bleaching strips (Crest Whitestrips)
Number of subjects: 34
Study 11153017 — intervention group
Group type: EXPERIMENTAL
Intervention: ST patients
Number of subjects: 56
Study 11153017 — intervention group
Group type: EXPERIMENTAL
Intervention: ST patients without atheroma of DTA
Number of subjects: 56
Study 8783893 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0
Study 8783893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1610984 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (MaxEPA)
Number of subjects: 16
Study 1610984 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 16
Study 1610984 — intervention group
Group type: COMPARATOR
Intervention: Fish oil (MaxEPA) and Placebo (olive oil)
Number of subjects: 16
Study 6475509 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression screw
Number of subjects: 255
Study 6475509 — intervention group
Group type: COMPARATOR
Intervention: Nail plate
Number of subjects: 255
Study 31273817 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression-free survival
Number of subjects: 0
Study 31273817 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 0
Study 28932913 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue-selecting technique (TST)
Number of subjects: 80
Study 28932913 — intervention group
Group type: COMPARATOR
Intervention: Transanal hemorrhoidal dearterialization (THD)
Number of subjects: 80
Study 24838598 — intervention group
Group type: EXPERIMENTAL
Intervention: R-T-R (reading, self-testing, rereading)
Number of subjects: 0
Study 24838598 — intervention group
Group type: COMPARATOR
Intervention: R-R-R (reading three consecutive times)
Number of subjects: 0
Study 24838598 — intervention group
Group type: COMPARATOR
Intervention: R-R + N (reading, taking notes, rereading)
Number of subjects: 0
Study 22905891 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg i.v. followed by paracetamol 2 g i.v. 30 min later
Number of subjects: 18
Study 22905891 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 2 g i.v.
Number of subjects: 18
Study 20852881 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox (79% helium‐21% oxygen)
Number of subjects: 11